BioCentury
ARTICLE | Clinical News

Elamipretide ophthalmic solution 1%: Phase II started

June 20, 2016 7:00 AM UTC

Stealth began the double-blind, placebo-controlled, U.S. Phase II ReSIGHT trial to evaluate twice-daily topical elamipretide eye drops for 12 weeks in about 12 patients. Patients will receive elamipre...